Abstract
We succeeded overproduction of the HBV envelope L particles with an approximate average particle size of 80 nm in yeast cells. Because the L particle is an empty bionanoparticles containing no viral DNA, it can be used as a safe and efficient carrier for human liver-specific delivery (pinpoint delivery) of drug and gene. In addition, genetically engineered L particles that are able to target to various organs were constructed by deleting the hepatocyte binding domain of L protein (pre-S region) and displaying targeting peptide or protein ligands. Therefore, bionanoparticles are a novel nano-carrier applicable to the broad range of pinpoint DDS. © 2006, THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM. All rights reserved.
Author supplied keywords
Cite
CITATION STYLE
Kondo, A., Kuroda, S. ichi, Tanizawa, K., Seno, M., & Ueda, M. (2006). Development of dds using hollow bio-nanoparticles and their commercialization. Drug Delivery System, 21(4), 435–443. https://doi.org/10.2745/dds.21.435
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.